Navigation Links
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
Date:3/24/2011

AUSTIN, Texas, March 24, 2011 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer.  OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service. 

"The use of biomarker tools throughout drug development is a requirement for researchers who must balance leaner R&D budgets with the greater demands for safety, innovation and success," said Craig Benson, RBM president and chief executive officer. "From one drop of serum, OncologyMAP® can deliver data that could help solve therapeutic and diagnostic dilemmas related to cancer making this biomarker panel an essential component of the development toolkit."

OncologyMAP® provides drug researchers with an accurate and affordable means of evaluating the efficacy and safety of therapeutic candidates. The test is validated to clinical laboratory standards enabling biomarker pattern discoveries made in basic research to be reproducibly extended into clinical trials. The use of sensitive, reproducible biomarker patterns as objective measures of drug efficacy and toxicity can accelerate development efforts and facilitate decision-making to avoid costs associated with late-stage drug attrition.

OncologyMAP® is based on RBM's proprietary Multi-Analyte Profiling (MAP) platform, which quantifies key blood-based biomarkers representing dozens of important biological pathways. The multiplexing process allows for heightened efficiency while providing excellent accuracy and precision.

This project was supported with Federal Funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contracts No. HHSN261200700037C and HHSN261200800045C.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at www.rulesbasedmedicine.com.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
2. Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
3. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
4. China Medicine Announces Strong Second Quarter 2008 Results
5. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
6. As personalized, genomic medicine takes off, four developing countries show the way for others
7. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
8. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
9. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
10. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
11. Dr. Larry Corey Named New Member of the Institutes of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... announced that the CTNext board of directors has formed a Higher Education Entrepreneurship ... working group composed of institution presidents and other high-ranking representatives from 35 higher ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... PhD, a well-versed leader with extensive assay development and biomarker expertise, as VP ... is a Boston CRO specializing in bio-analytical assay development and sample testing services. ...
(Date:6/19/2017)... ... 2017 , ... EDETEK, Inc., a clinical technology company focused ... two new additions of its award-winning cloud-based platform CONFORM™: Information Hub and Clinical ... Annual Meeting in Chicago, IL, June 19-22, 2017. , “Modern clinical trials use ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... today announced that its Anzo Smart Data Lake® (Anzo SDL) solution was ... for the 2017 Software & Information Industry Association (SIIA) CODiE Awards. , ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):